Download PDF
Thromb Haemost 2001; 86(06): 1343-1344
DOI: 10.1055/s-0037-1616732
Commentary
Schattauer GmbH

Co-stimulation Blockade, Hemophilic Inhibitors and Tolerance

Jiahua Qian
1   Departments of Immunology
,
Evgueni Saenko
2   Biochemistry, Holland Laboratory of the American Red Cross, Rockville, MD, USA
,
David Scott
1   Departments of Immunology
› Author Affiliations
Further Information

Publication History





Publication Date:
12 December 2017 (online)

Also available at
    Permissions and Reprints

 

 

  • References

  • 1 Qian J, Collins M, Sharpe AH, Hoyer LW. Prevention and treatment of factor VIII inhibitors in murine hemophilia A. Blood 2000; 95: 1324-9.
    PubMedGoogle Scholar
  • 2 Noelle RJ, Ledbetter JA, Aruffo A. CD40 and its ligand, an essential ligand-receptor pair for thymus-dependent B-cell activation. Immunol Today 1992; 13: 431-3.
    CrossrefPubMedGoogle Scholar
  • 3 Van den Eertwegh AJ, Noelle RJ, Roy M, Shepherd DM, Aruffo A, Ledbetter JA, Boersma WJ, Claassen E. In vivo CD40-gp39 interactions are essential for thymus-dependent humoral immunity. I. In vivo expression of CD40 ligand, cytokines, and antibody production delineates sites of cognate T-B cell interactions. J Exp Med 1993; 178: 1555-65.
    CrossrefPubMedGoogle Scholar
  • 4 Han S, Hathcock K, Zheng B, Kepler TB, Hodes R, Kelsoe G. Cellular interaction in germinal centers. Roles of CD40 ligand and B7-2 in established germinal centers. J Immunol 1995; 155: 556-67.
    PubMedGoogle Scholar
  • 5 Foy TM, Laman JD, Ledbetter JA, Aruffo A, Claassen E, Noelle RJ. gp39-CD40 interactions are essential for germinal center formation and the development of B cell memory. J Exp Med 1994; 180: 157-63.
    CrossrefPubMedGoogle Scholar
  • 6 Noelle RJ, Mackey M, Foy T, Buhlmann J, Burns C. CD40 and its ligand in autoimmunity. Ann N Y Acad Sci 1997; 815: 384-91.
    CrossrefPubMedGoogle Scholar
  • 7 Waldmann H. Transplantation tolerance – where do we stand?. Nat Med 1999; 5: 1245-8.
    CrossrefPubMedGoogle Scholar
  • 8 Ewenstein BM, Hoots WK, Lusher JM, DiMichele D, White 2nd GC, Adelman B, Nadeau K. Inhibition of CD40 ligand (CD154) in the treatment of factor VIII inhibitors. Haematologica 2000; 85 10 Suppl 35-9.
    PubMedGoogle Scholar
  • 9 Kirk AD, Harlan DM, Armstrong NN, Davis TA, Dong Y, Gray GS, Hong X, Thomas D, Fechner Jr JH, Knechtle SJ. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci USA 1997; 94: 8789-94.
    CrossrefPubMedGoogle Scholar
  • 10 Kirk AD, Burkly LC, Batty DS, Baumgartner RE, Berning JD, Buchanan K, Fechner Jr JH, Germond RL, Kampen RL, Patterson NB. et al. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat Med 1999; 5: 686-93.
    CrossrefPubMedGoogle Scholar
  • 11 Qian J, Burkly LC, Smith EP, Ferrant JL, Hoyer LW, Scott DW, Haudenschild CC. Role of CD154 in the secondary immune response: the reduction of pre-existing splenic germinal centers and anti-factor VIII inhibitor titer. Eur J Immunol 2000; 30: 2548-54.
    CrossrefPubMedGoogle Scholar
  • 12 Rossi G, Sarkar J, Scandella D. Long-term induction of immune tolerance after blockade of CD40-CD40L interaction in a mouse model of hemophilia A. Blood 2001; 97: 2750-7.
    CrossrefPubMedGoogle Scholar
  • 13 Jahreis A, Homann D, Wolfe T, Hughe A, Coon B, von Stipendonk M, Schonberber S, von Harath M. Blockade of CD40L during activation of the auto-aggressive response prevent autoimmune diabetes by inducing regulatory Cd11c antigen presenting cells. Abstract, 11th International Congress of Immunology. 2001, W 3.6.
    PubMedGoogle Scholar